Literature DB >> 15249136

Expression of myelencephalon-specific protease in transient middle cerebral artery occlusion model of rat brain.

Atsushi Uchida1, Yuichi Oka, Mineyoshi Aoyama, Shugo Suzuki, Takashi Yokoi, Hiroyuki Katano, Mitsuhito Mase, Toyohiro Tada, Kiyofumi Asai, Kazuo Yamada.   

Abstract

Myelencephalon-specific protease (MSP) is one of the serine proteases and is expressed in the central nervous system of rats. Its function and alternation in brain injury have not yet been clarified. In this study, we investigated the expression of MSP after transient middle cerebral artery occlusion (MCAO) using in situ hybridization and immunohistochemistry. In situ localization of MSP mRNA demonstrated a higher level in the corpus callosum and around the ischemic area from 12 h to 14 days after MCA reperfusion, with the peak of expression coming 3 days after reperfusion in both regions. Immunohistochemically, the expression of protein was found 1 day after reperfusion in the same brain region that was observed for mRNA. The peak was 7 days after reperfusion in both regions. Micro-autoradiography, immunostaining and double immunohistochemical labeling revealed the expression of MSP to be located mainly in the oligodendrocytes. The present results indicate that MSP may be related to the turnover of the myelin-associated proteins and the extracellular matrix proteins after transient MCAO. The activation of MSP may play a role in remodeling processes such as neurite outgrowth and remyelination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249136     DOI: 10.1016/j.molbrainres.2004.04.009

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  8 in total

1.  Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Authors:  Isobel A Scarisbrick; Maja Radulovic; Joshua E Burda; Nadya Larson; Sachiko I Blaber; Caterina Giannini; Michael Blaber; Alexander G Vandell
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

2.  Blocking Kallikrein 6 promotes developmental myelination.

Authors:  Hyesook Yoon; Erin M Triplet; Whitney L Simon; Chan-Il Choi; Laurel S Kleppe; Elena De Vita; Aubry K Miller; Isobel A Scarisbrick
Journal:  Glia       Date:  2021-10-09       Impact factor: 7.452

3.  Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Authors:  Isobel A Scarisbrick; Rachel Linbo; Alexander G Vandell; Mark Keegan; Sachiko I Blaber; Michael Blaber; Diane Sneve; Claudia F Lucchinetti; Moses Rodriguez; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

4.  Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis.

Authors:  Isobel A Scarisbrick; Hyesook Yoon; Michael Panos; Nadya Larson; Sachiko I Blaber; Michael Blaber; Moses Rodriguez
Journal:  Brain Pathol       Date:  2012-03-21       Impact factor: 6.508

5.  Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms.

Authors:  Hyesook Yoon; Maja Radulovic; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2018-09-25       Impact factor: 3.915

6.  Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines.

Authors:  Alexander G Vandell; Nadya Larson; Gurunathan Laxmikanthan; Michael Panos; Sachiko I Blaber; Michael Blaber; Isobel A Scarisbrick
Journal:  J Neurochem       Date:  2008-09-06       Impact factor: 5.372

7.  Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity.

Authors:  Hyesook Yoon; Maja Radulovic; Jianmin Wu; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neurochem       Date:  2013-05-27       Impact factor: 5.372

8.  Correlation between KLK6 expression and the clinicopathological features of glioma.

Authors:  Jiangtao Lou; Haiyan Si; Yingjian Chen; Xiaoming Sun; Hua Zhang; Aijun Niu; Chengjin Hu
Journal:  Contemp Oncol (Pozn)       Date:  2014-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.